Shire Initiates Two Adult ADHD Outreac...( ...)

PHILADELPHIA, Aug. 17 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced two initiatives reinforcing their commitment to the care of adults with Attention-Deficit/Hyperactivity Disorder (ADHD), a psychiatric behavioral disorder that affects an estimated 10 million adults across the country.* The first initiative, "RoADHD Trip," a multi-city self screening tour, will visit eight cities across the country in an effort to raise awareness that ADHD in adults is a real and treatable medical disorder. The second initiative, ADHD Clinical Education (ACE) Program, includes a field-based team of experienced psychiatric nurses who will provide in-office education to physicians and their staff on ADHD in adults.

"These programs demonstrate that adults with ADHD have Shire's full attention. We are committed to providing information not only to adults who may be struggling with the symptoms of the disorder, but also to the physicians who treat them," said Michael Yasick, Senior Vice President of the ADHD Business Unit at Shire. "Our 2008 screening outreach initiative was very successful at raising awareness -- nearly 52,000 adults self-screened. We are happy to continue this program and take awareness one step further by providing additional education to physicians, as well."

About RoADHD Trip and ACE Programs

"RoADHD Trip" provides the opportunity for adults who think they may have ADHD to take the first step toward recognizing the symptoms of the disorder by completing a six-question World Health Organization (WHO) adult ADHD self-screener. Shire is partnering with the Attention Deficit Disorder Association (ADDA), a leading adult ADHD patient advocacy
'/>"/>